EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Combining an immunomodulatory drug with a TPO‐RA to treat multirefractory ITP patients: The Spanish ITP Group experience

María-Eva Mingot-Castellano iD, Patricia Alcalde-Mellado, Laura Entrena-Ureña, Cristina Pascual-Izquierdo, Denis Zafra-Torres, Mariana Canaro Hirnyk, José-María Bastida, Silvia Bernat-Pablo, Daniel Martínez-Carballeira, Isabel-Socorro Caparrós-Miranda, Amalia Cuesta-García, Sunil Lakhwani iD und 14 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70306 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Haematology, 2026. Verfasst von María-Eva Mingot-Castellano und 25 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla, Sevilla, Spain. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Receptors, Thrombopoietin, Thrombopoietin, Recombinant Fusion Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multirefractory immune thrombocytopenia (ITP) is difficult to manage. The simultaneous administration of an immunosuppressive/immunomodulatory drug (IS/IM) and a thrombopoietin receptor agonist (TPO‐RA) is increasingly used. We present the experience of the Spanish ITP Group in this retrospective, observational study. Ninety‐seven patients with ≥3 failed treatment lines were administered combination therapy (CT) with an IS/IM and a TPO‐RA between January 2021 and December 2023. The IS/IMs were steroids, purine synthesis inhibitors and fostamatinib. The TPO‐RAs were romiplostim, eltrombopag and avatrombopag. Seventy‐five (77.3%) patients responded to treatment in a median (interquartile range [IQR]) time of 14 (7–52) days. An inverse correlation between previous failures and response was observed (Rho = −0.290, p = 0.009). After 840 (448–1054) days, relapse was reported in 35 (46.7%) of 75 responders (time to relapse: 197 [47–402] days). Relapse was more frequent in chronic ITP patients. Twenty‐one patients received a second CT after failure of the first one. Eleven were administered a third CT for the same reason. Response and relapse were similar to those observed with the first CT. Three thromboembolic events and 14 infections that required hospitalization were reported, none fatal. The combination of IS/IMs and TPO‐RAs arises as an alternative option of treatment in multirefractory ITP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicReceptors, ThrombopoietinThrombopoietinRecombinant Fusion ProteinsImmunomodulating AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedHydrazinesSpainDrug Therapy, CombinationPyrazolesBenzoatesAdultReceptors, FcTreatment OutcomeThiazolesThiophenes

Stichwörter der Autor:innen

combinationcorticosteroidsimmune thrombocytopeniaimmunomodulationrefractorinessthrombopoietin receptor agonists

Substanzen

Receptors, ThrombopoietinHydrazineseltrombopagromiplostimPyrazolesThrombopoietinBenzoatesRecombinant Fusion ProteinsImmunomodulating Agentsavatrombopag

Autor:innen und Institutionen

  • Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Universidad de Sevilla, Sevilla, Spain.
  • Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), Sevilla, Spain.
  • Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Hospital 12 de Octubre, Madrid, Spain.
  • Hospital Universitario Son Espases, Palma de Mallorca, Spain.

ORCID-Profile: María-Eva Mingot-Castellano, Sunil Lakhwani

Zitieren

APA

Mingot-Castellano, M. E., Alcalde-Mellado, P., Entrena-Ureña, L., Pascual-Izquierdo, C., Zafra-Torres, D., Canaro Hirnyk, M., Bastida, J. M., Bernat-Pablo, S., Martínez-Carballeira, D., Caparrós-Miranda, I. S., Cuesta-García, A., Lakhwani, S., Sánchez-González, B., Canet-Maldonado, M., Gómez-Del-Castillo-Solano, M. D., García-Culebras, M., Chiclana-Rodríguez, B., Fernández-Villalobos, M., Sánchez-Llorca, P., …, & Spanish ITP Group (GEPTI) (2026). Combining an immunomodulatory drug with a TPO‐RA to treat multirefractory ITP patients: The Spanish ITP Group experience. British Journal of Haematology. https://doi.org/10.1111/bjh.70306

Vancouver

Mingot-Castellano ME, Alcalde-Mellado P, Entrena-Ureña L, Pascual-Izquierdo C, Zafra-Torres D, Canaro Hirnyk M, et al. Combining an immunomodulatory drug with a TPO‐RA to treat multirefractory ITP patients: The Spanish ITP Group experience. British Journal of Haematology. 2026. doi:10.1111/bjh.70306

BibTeX
@article{MingotCastellano2026,
  author = {Mingot-Castellano, María-Eva and Alcalde-Mellado, Patricia and Entrena-Ureña, Laura and Pascual-Izquierdo, Cristina and Zafra-Torres, Denis and Canaro Hirnyk, Mariana and Bastida, José-María and Bernat-Pablo, Silvia and Martínez-Carballeira, Daniel and Caparrós-Miranda, Isabel-Socorro and Cuesta-García, Amalia and Lakhwani, Sunil and Sánchez-González, Blanca and Canet-Maldonado, Marta and Gómez-Del-Castillo-Solano, María-Del-Carmen and García-Culebras, Marta and Chiclana-Rodríguez, Beatriz and Fernández-Villalobos, Manuel and Sánchez-Llorca, Paula and Piquer-Monsonís, Dolores and Puerta-Vázquez, Carlos and Pérez-Montes, Rocío and García-Pallarols, Francesc and Poza-Santaella, María and Pedrote-Amador, Begoña and Spanish ITP Group (GEPTI), Spanish ITP Group (GEPTI)},
  title = {Combining an immunomodulatory drug with a TPO‐RA to treat multirefractory ITP patients: The Spanish ITP Group experience},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70306}
}
Kostenlos starten →